before and after semaglutide weight loss After: Real Results The Pros and Cons of

The SURPASS-2 trial directly compared the two for type 2 diabetes and found tirzepatide superior at all dose levels

Around 3,800 participants were enrolled across both trials, randomized to placebo or oral semaglutide 14 mg daily for up to 104 weeks (~2 years)

It reflects a normal physiological response to weight loss

Semaglutide targets the GLP-1 pathway, while tirzepatide activates both GLP-1 and GIP receptors, creating a dual-hormone effect that may influence blood sugar, satiety, and fat metabolism more comprehensively

There are thousands more reports concerning Wegovys sister drugs, Ozempic and Rybelsus, and the generic drug, semaglutide